Attached files
file | filename |
---|---|
EX-21.1 - EX-21.1 - Adagio Therapeutics, Inc. | d549501dex211.htm |
EX-10.8 - EX-10.8 - Adagio Therapeutics, Inc. | d549501dex108.htm |
EX-10.7 - EX-10.7 - Adagio Therapeutics, Inc. | d549501dex107.htm |
EX-10.6 - EX-10.6 - Adagio Therapeutics, Inc. | d549501dex106.htm |
EX-10.5 - EX-10.5 - Adagio Therapeutics, Inc. | d549501dex105.htm |
EX-10.1 - EX-10.1 - Adagio Therapeutics, Inc. | d549501dex101.htm |
EX-4.1 - EX-4.1 - Adagio Therapeutics, Inc. | d549501dex41.htm |
EX-3.2 - EX-3.2 - Adagio Therapeutics, Inc. | d549501dex32.htm |
EX-3.1 - EX-3.1 - Adagio Therapeutics, Inc. | d549501dex31.htm |
S-1 - S-1 - Adagio Therapeutics, Inc. | d549501ds1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form S-1 of Adagio Therapeutics, Inc. of our report dated May 21, 2021 relating to the financial statements of Adagio Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading Experts in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
July 16, 2021